FDA Investigator Norman K Starks

Norman K Starks has inspections in 2 countries as of 29 Sep 2023. Norman K Starks has collaborated with a combinined 3414 experts on various inspections, contributing to compliance and improvement across diverse sectors.

Investigator Details

Number of Inspected Sites:
40
Last Inspection Date:
29 Sep 2023
Investigator Role:
FDA Investigator
Redica ID:
Country:
United States of America, Israel
Co-Investigator(s):
Alan M Roberts, Alicia M Mozzachio, Ana L Kewes, Anders W Evenson, Anthony J Ladner, Ashley L Reiber, Barbara J Holladay, Barbara Janine Breithaupt, Brett R Havranek, Brian D Nicholson, Bruce H Mccullough, Bruce M Mccullough, Bryan L Mcguckin, Bryce H Thompson, Byungja E Marciante, Carl A Huffman, III, Carrie Ann Plucinski, Cassandra L Abellard, Chad J Whitwell, Chaltu N Wakijra, Charles L Zhou, Charles R Bonapace, PhD, Charles R Cole, Charles R Cote, RIC, Chilton L Ng, Christian D Lynch (CDL), Christina A Miller, Christina K Theodorou, Christine M Smith, Christine Mwhitby Smith, Christopher D Leach, Concepcion Cruz, Jr, Constantin Y Philopoulos, Courtney E Hillier, Cynthia A Harris, MD, RN, Cynthia J Lee, MS, Cynthia Jim, CSO, Cynthia M Goudeau, Dacia E Quick, Dale A Nyberg, Daniel R Azar, Dariusz Galezowski, David Perkins, Debra Bower, Debra I Love, Denarvis C Mendenhall, Dennis L Doupnik, Derek S Smith, PhD, Dewayne E Whitlock, Deyaa Shaheen, Donna K Speer, Douglas A Campbell, Douglas R Nelson, Dr. Mark J Seaton, PhD, Dr. Zhou Chen (nmi), MD PhD, Emest F Bizjak, Emmanuel A Dimaano, Jr, Enrico Joset Mangahis, Eric M Mueller, PharmD, Erika V Butler, Erin L Mcfiren, Gerald E Scholze, Gloria J Champagne, Greg Brinsley, Gregory R Brinsley, Gwyn G Dickinson, Ingrid Y Johnson, Jacqueline Mdiaz Albertini, James P Duggan, James P Mcreavey, James W Plucinski, Janet B Abt, Jeanne M Morris, Jesse P Romenesko, Jessica D Nanini, Joohi Castelvetere, Jose Alopez Rubet, Jose R Hernandez, Joseph R Lambert, Joshua M Adams, Julie D Bringger, Justin A Boyd, Jyoti B Patel, PhD, Katherine E Jacobitz, Kathleen S Tormey, Kenneth A Libertoski, Kenneth Nieves, Kerry L Edwards, III, Kevin P Regan, Kurt A Brorson, PhD, Lakisha M Williams, Lata C Mathew, PhD, Laura A Adam, Leonard H Lavi, Lequita M Mayhew, Lindsey S Fleischman, Lisa Hayka, Lisa Hornback, Lisa L Flores, Loan Chin, Logan M Ebeling, Luis M Burgos, Luis M Burgos Medero, Lynette P Salisbury, Maksim A Levenchuk, Marcia A Worley, Marcus A Ray, Margaret M Annes, Marie Bbuen Bigornia, Mark G Peterson, Mary G Leadbetter, Matthew M Schuckmann, Michael A Charles, Michael D Smedley, Michael F Skelly, PhD, Michael S Araneta, Michael S Kopf, Michael Y Philopoulos, Michele L Glendenning, Michele Perry Williams, Michelle L Dragon, Monica E Murie, Monica M Mcclure, Muna Algharibeh, Nebil A Oumer, Nibin Varghese, MS, Nicholas F Lyons, Nicholas P Diorio, Nicholas Z Lu, Pablo Alcantara, Paola E Lathrop, Patricia A Mcilroy, Patrick J Campbell, Paula J Bretz, Paula P Demichael, Peng Zhou, Philip J Snoy, Pratik S Upadhyay, DDC, Rachel C Harrington, Rachel T Evans, Rafael Padilla, Rebecca L Mullikin, Richard Heath Coats, Rita K Kabaso, Robert D Tollefsen, Robert J Doyle, Robert J Ham, Robert L Hummel, Rose M Ashley, Russell K Riley, Samuel A Hamblin, Sandra A Boyd, Sandra A Hughes, Shafiq S Ahadi, Sharon K Thoma, PharmD, Sherry G Bous, Simone E Pitts, Soyinka S Eneng, State Agency, Stefen D Mcmillan, Stephanie L Shapley, Steven D Kehoe, Steven P Donald, Sullan, Susan D Yuscius, Susan M Jackson, Susan P Bruederle, Tamara Brey, Tara L Breckenridge, Tara L Greene, Tarsha T Mcclendon, That Q Dang, Theresa C Klaman, Thomas J Arista, Timothy S Roddy, Todd Q Dang, Toyin B Oladimeji, Vioela J Caze, Walden H Lee, Warren J Lopicka, Wayne T Smith, William A Warnick, William D Sherman, Yvesna C Blaise, Yvonne E Lozano, Zachary L Miller, Zhongren Wu

Norman K Starks's Documents

Publish Date Document Type Title
September, 2021 FDA 483 Accelerated Analytical - Form 483, 2021-09-27
November, 2021 FDA 483 Response FIRST PRIORITY INCORPORATED - Form 483R, 2021-12-10
February, 2022 EIR PQ Corporation - EIR, 2022-02-22
July, 2022 FDA 483 Response BAMF Health, Inc. - Form 483R, 2022-07-01
July, 2022 FDA 483 BAMF Health, Inc. - Form 483, 2022-07-01
June, 2017 EIR DENTAL TECHNOLOGIES, INC. - EIR, 2017-06-29
March, 2018 FDA 483 Xttrium Laboratories, Inc. - Form 483, 2018-03-15
September, 2018 FDA 483 JCB Laboratories LLC - Form 483, 2018-09-14
February, 2022 FDA 483 PQ Corporation - Form 483, 2022-02-22
September, 2019 FDA 483 Snyder Mark Drugs Roselle, Inc. d.b.a. Mark Drugs Pharmacy - Form 483, 2019-09-27
September, 2022 FDA 483 Sigan America, LLC - Form 483, 2022-09-01
January, 2019 EIR McCrone Associates, Inc. - EIR, 2019-02-04
November, 2021 EIR FIRST PRIORITY INCORPORATED - EIR, 2021-11-18
November, 2021 FDA 483 FIRST PRIORITY INCORPORATED - Form 483, 2021-11-18
June, 2021 FDA 483 Agnitio Inc. - Form 483, 2021-06-04
February, 2023 FDA 483 Finish Line Horse Products Inc. - Form 483, 2023-02-16
July, 2022 EIR BAMF Health, Inc. - EIR, 2022-07-01
April, 2022 FDA 483 Accugen Laboratories, Inc. - Form 483, 2022-04-22
August, 2022 FDA 483 Consolidated Chemical, Inc. DBA CARE-TECH Laboratories, Inc. - Form 483, 2022-08-02
May, 2023 FDA 483 ChRi Laboratories, Inc - Form 483, 2023-05-03
May, 2018 EIR Avatar Corporation - EIR, 2023-10-20
May, 2022 FDA 483 Zoetis LLC - Form 483, 2022-05-23

Experience Redica System's NEW investigator profiles and dashboards

Redica Systems customers get access to over 1,400 FDA Investigator profiles, containing powerful analysis like:

  • Total inspections conducted
  • 483 rate
  • OAI rate
  • Warning Letter rate
  • Inspections by Industry, Scope, and Inspection Reason
  • And much more

Investigator Profiles are not sold as on-demand documents. If you’d like to see one, fill out the form below to connect with our Sales Team and get it in your inbox as little as 24 hours.

FDA Investigator Profile Icon

Talk to sales to access our investigator profiles

Loading...

Investigator Profiles Are Just the Tip of the Iceberg

Becoming a Redica Systems customer not only provides you with unlimited access to profiles similar to the one above for every current and former FDA Investigator, but also grants you access to:

Inspection Intelligence

  • Pre-Approval Inspection (PAI) trends
  • The ability to filter nearly any FDA enforcement action by GxP labels like GMP, GCP, etc.
  • Latest 483s: see what the trends are across all FDA Investigators
  • CFR Heatmap: Citations aggregated by Subpart by Year

Vendor Intelligence

  • Full inspection histories for your vendors down to the specific site level
  • All of the functionality mentioned above but isolated to just your vendors

Regulatory Intelligence

  • Zero in on the trends for a specific agency/regulator (ex. FDA, MHRA, EMA, Health Canada)
  • All the latest "Signals" from agencies around the world, segmented by Country, Type (ex. Guidance, Decree...), Category (ex. Rules/Regulations/Guidance, News, Reports...), Theme (ex. Cell and Gene Therapy, AI...), and more